ArticleChinese medicine2025
Inter-species and individualized biotransformation of five saponins by human being- and mouse-derived fecal microbiota.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic Review: Exploring Inter-Species Variability in Diabetes Mellitus for Translational Medicine.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe gut microbiota plays a critical role in the biotransformation of saponins. However, current research predominantly focuses on metabolism by single microbial species, with limited investigation into inter-species differences or inter-individual variability in saponin biotransformation, especially by the culture of mixed gut microbiota. This study aims to elucidate the species-specific differences and inter-individual variability in gut microbiota-mediated saponin biotransformation through multidimensional analysis.
methodsIn this study, we selected five representative saponins, including ginsenoside Rb1, ginsenoside Re, glycyrrhizic acid, saikosaponin D and dioscin, and conducted anaerobic cultures ex vivo with mixed gut microbiota derived from mice and humans. Metabolic profiles of parent compounds and their metabolites were analyzed using UPLC-MS/MS. Additionally, three saponins (ginsenoside Rb1, glycyrrhizic acid and saikosaponin D) were co-cultured with gut microbiota from 50 healthy volunteers to assess inter-individual biotransformation variability. 16S rRNA gene sequencing was employed to identify key microbial taxa and potential metabolic pathways.
resultsWe revealed distinct biotransformation patterns of multi-component saponins by mixed gut microbiota, with notable inter-individual variability observed among 50 healthy volunteers. Particularly, ginsenoside Rb1 exhibited the most significant individual differences in gut microbiota biotransformation. Further analysis demonstrated that the biotransformation capacity of gut microbiota was closely correlated with both its taxonomic composition and the relative abundances of specific bacterial genera.
conclusionThis study elucidated the pivotal role of gut microbiota in mediating inter-individual differences in saponin biotransformation, while having identified potential microbial communities and metabolic pathways involved in saponin biotransformation. These findings not only advance understanding of species-dependent biotransformation of saponins but also establish a foundation for screening microbial strains or enzymes to optimize saponin-derived therapies, thereby facilitating precision medicine and translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.